Showing 2,946 results

Filters Content type: News, Editors' picks, About HIV Topic: PrEP

Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP).

Transgender people

Major US cohort reveals sharp racial disparities in HIV acquisition among trans women

News
2 March 2026
HIV testing programmes & uptake

Home visits and flexible PrEP cut HIV incidence by 70% in rural Kenya and Uganda

News
2 March 2026
PrEP policies & guidelines

RFK Jr. May Eliminate the U.S. Preventive Services Task Force

Editor's pick
MedPage Today (requires free registration)
1 March 2026
Injectable & long-acting PrEP

Islatravir PrEP didn’t protect against M184V mutation in macaque study

Editor's pick
i-Base
1 March 2026
Injectable & long-acting PrEP

New research: High prevention efficacy and “breakthrough infections” on lenacapavir for PrEP

Editor's pick
San Francisco AIDS Foundation
1 March 2026
Injectable & long-acting PrEP

Long-Acting Cabotegravir Shows High PrEP Effectiveness in Black Women

Editor's pick
Infectious Disease Advisor
27 February 2026
Injectable & long-acting PrEP

Zimbabwe’s Lenacapavir rollout: The gap between hope and truth

Editor's pick
Be In The Know
27 February 2026
PrEP programmes & uptake

PrEP uptake was already low – and then came the cuts

News
26 February 2026
PrEP programmes & uptake

French study confirms efficacy of on-demand PrEP

News
24 February 2026
Injectable & long-acting PrEP

Zimbabwe Rolls Out New HIV Prevention Drug Lenacapavir

Editor's pick
Medscape (requires free registration)
23 February 2026
PrEP

Tenofovir alafenamide / emtricitabine for PrEP

About HIV
February 2026
PrEP

Tenofovir disoproxil / emtricitabine for PrEP

About HIV
February 2026
Injectable & long-acting PrEP

Cabotegravir injections for PrEP

About HIV
February 2026
PrEP

Pre-exposure prophylaxis (PrEP)

About HIV
February 2026
Access to healthcare

Civil Society Demands Access Strategy for Merck’s Promising Long-Acting HIV Prevention Pill Covering all Low- and Middle-Income Countries

Editor's pick
Health GAP (Global Access Project)
12 February 2026
Access to healthcare

Twice-Yearly Lenacapavir Injection for HIV Prevention in Nigeria: The Real Test Is Access

Editor's pick
Nigeria Health Watch
6 February 2026
PrEP policies & guidelines

Where is HIV prevention drug lenacapavir in ‘America First’ health deals?

Editor's pick
Devex (requires free registration)
6 February 2026
PrEP policies & guidelines

US: ‘Transformative’ HIV PrEP shot slowly overcomes cost hurdles

Editor's pick
The Hill
1 February 2026
PrEP policies & guidelines

Malta: Government rolls out free HIV prevention medicines PEP and PrEP

Editor's pick
Malta Today
30 January 2026
Access to healthcare

New US research: Out of thousands, only 42 people started long-acting injectable PrEP

Editor's pick
San Francisco AIDS Foundation
26 January 2026
Access to healthcare

US: PrEP Users Applaud CVS and Gilead Agreement on Yeztugo

Editor's pick
PrEP4All
15 January 2026
Injectable & long-acting HIV treatment

Lenacapavir Resistance May Impair HIV Fitness

Editor's pick
POZ
12 January 2026
Access to healthcare

To Knock Down Health-System Hurdles Between You and HIV Prevention, Try These 6 Things

Editor's pick
KFF Health News
9 January 2026
PrEP science

Event-based PrEP dosing for women: a challenge to guidelines and an activist issue

Editor's pick
i-Base
6 January 2026